Optimizing IVIg in Xenotransplantation: A Call to Action

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD.
² Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.
³ Department of Pharmacy, Johns Hopkins University, Baltimore, MD.

Robin K Avery et al. Transplantation. 2025.

. 2025 Apr 1.

doi: 10.1097/TP.0000000000005402. Online ahead of print.

¹ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD.
² Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD.
³ Department of Pharmacy, Johns Hopkins University, Baltimore, MD.

No abstract available

References

1. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation. 2001;71:242–246.
1. Mohiuddin MM, Singh AK, Scobie L, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac transplantation: a case report. Lancet. 2023;402:397–410.
1. Cooper DKC, Yamamoto T, Hara H, et al. The first clinical pig heart transplant: was IVIg or pig cytomegalovirus deleterious to the outcome? Xenotransplant. 2022;29:e12771.
1. Hisadome Y, Eisenson DL, Santillan MR, et al. Pretransplant screening for prevention of hyperacute graft loss in pig-to-primate kidney xenotransplantation. Transplantation. 2024;108:1749–1759.
1. Liu J, Qian Y, Holgersson J. Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins containing the Gal alpha1, 3Gal epitope. Transplantation. 1997;63:1673–1682.